Regeneron Pharmaceuticals Q1 Profit Increases, But Misses Estimates

Regeneron Pharmaceuticals (REGN) reported a profit for its first quarter that increased from the same period last year but missed the Street estimates.

The company's bottom line came in at $808.7 million, or $7.27 per share. This compares with $722.0 million, or $6.27 per share, last year.

Excluding items, Regeneron Pharmaceuticals reported adjusted earnings of $928.4 million or $8.22 per share for the period.

Analysts on average had expected the company to earn $8.48 per share. Analysts' estimates typically exclude special items.

The company's revenue for the period fell 3.7% to $3.028 billion from $3.145 billion last year.

Regeneron Pharmaceuticals earnings at a glance (GAAP) :

-Earnings: $808.7 Mln. vs. $722.0 Mln. last year.
-EPS: $7.27 vs. $6.27 last year.
-Revenue: $3.028 Bln vs. $3.145 Bln last year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com